Novavax (NVAX) Competitors $8.62 +0.29 (+3.48%) Closing price 04:00 PM EasternExtended Trading$8.67 +0.05 (+0.58%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVAX vs. MRNA, OCGN, VXRT, JNJ, PFE, ALKS, LGND, FOLD, CLDX, and MNKDShould you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Moderna (MRNA), Ocugen (OCGN), Vaxart (VXRT), Johnson & Johnson (JNJ), Pfizer (PFE), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), and MannKind (MNKD). These companies are all part of the "medical" sector. Novavax vs. Its Competitors Moderna Ocugen Vaxart Johnson & Johnson Pfizer Alkermes Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics MannKind Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership. Is MRNA or NVAX more profitable? Novavax has a net margin of 39.20% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Novavax's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% Novavax 39.20%-142.33%28.65% Do institutionals and insiders have more ownership in MRNA or NVAX? 75.3% of Moderna shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 11.0% of Moderna shares are held by insiders. Comparatively, 1.0% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to MRNA or NVAX? In the previous week, Moderna had 13 more articles in the media than Novavax. MarketBeat recorded 18 mentions for Moderna and 5 mentions for Novavax. Novavax's average media sentiment score of 0.57 beat Moderna's score of 0.54 indicating that Novavax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 5 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Novavax 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer MRNA or NVAX? Moderna presently has a consensus target price of $41.81, suggesting a potential upside of 56.37%. Novavax has a consensus target price of $12.33, suggesting a potential upside of 43.08%. Given Moderna's higher possible upside, equities research analysts clearly believe Moderna is more favorable than Novavax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 5 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.00Novavax 4 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings and valuation, MRNA or NVAX? Novavax has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.06B3.42-$3.56B-$7.53-3.55Novavax$682.16M2.05-$187.50M$2.283.78 Which has more risk and volatility, MRNA or NVAX? Moderna has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Novavax has a beta of 2.74, meaning that its stock price is 174% more volatile than the S&P 500. SummaryModerna and Novavax tied by winning 8 of the 16 factors compared between the two stocks. Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVAX vs. The Competition Export to ExcelMetricNovavaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.40B$3.33B$6.04B$10.44BDividend YieldN/A2.31%5.73%4.79%P/E Ratio3.7822.2285.3127.07Price / Sales2.05439.84588.57190.17Price / CashN/A44.9825.7330.17Price / Book-2.2210.3812.666.69Net Income-$187.50M-$52.31M$3.31B$276.03M7 Day Performance-5.07%0.59%-0.44%-1.13%1 Month Performance8.02%13.90%8.70%6.49%1 Year Performance-31.21%28.95%76.70%34.41% Novavax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVAXNovavax4.2335 of 5 stars$8.62+3.5%$12.33+43.1%-33.5%$1.40B$682.16M3.781,990MRNAModerna4.2459 of 5 stars$27.54-3.3%$41.81+51.8%-54.0%$10.72B$3.24B-3.665,800Analyst ForecastOCGNOcugen1.4893 of 5 stars$1.82+2.8%$6.00+229.7%+73.6%$531.99M$4.05M-9.1080VXRTVaxart2.4724 of 5 stars$0.36-1.0%$2.00+457.1%-55.8%$82.19M$47.40M-1.33120Gap UpJNJJohnson & Johnson4.668 of 5 stars$188.23-0.2%$189.12+0.5%+18.1%$453.32B$90.63B20.13138,100Trending NewsUpcoming EarningsAnalyst ForecastPFEPfizer4.9637 of 5 stars$26.45-3.4%$28.41+7.4%-14.9%$150.38B$63.83B14.0781,000Positive NewsDividend AnnouncementAnalyst ForecastAnalyst RevisionALKSAlkermes4.4841 of 5 stars$30.99-0.2%$42.00+35.5%+8.0%$5.12B$1.51B14.901,800Positive NewsLGNDLigand Pharmaceuticals4.001 of 5 stars$182.61+0.9%$176.50-3.3%+72.7%$3.58B$187.58M-45.6580FOLDAmicus Therapeutics4.5038 of 5 stars$8.16-0.5%$15.78+93.4%-21.0%$2.52B$571.16M-67.99480CLDXCelldex Therapeutics2.3271 of 5 stars$26.38-0.1%$46.13+74.8%-14.5%$1.75B$7.02M-8.76150News CoverageAnalyst ForecastGap DownMNKDMannKind4.0148 of 5 stars$5.66-1.7%$11.17+97.3%-24.7%$1.74B$285.50M51.46400News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Moderna Alternatives Ocugen Alternatives Vaxart Alternatives Johnson & Johnson Alternatives Pfizer Alternatives Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Celldex Therapeutics Alternatives MannKind Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVAX) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
